This phenotype was common in both IDCmet− and IDCmet+ patients (50% and 55% respectively) but very rare in DCIS (5%) (Figure 5C) where CCL21-expression instead was confined to αSMA+ FRCs (Figure S6A,B). Here, CCL21 is linked to ductal breast carcinoma in situ.